GlobeNewswire

ProMIS Neurosciences congratulates Biogen on FDA accelerated approval of aducanumab for Alzheimer’s disease

Share

Approval of aducanumab offers real hope for patients and fuels development of next-generation therapies with more selective binding for toxic species of amyloid beta

TORONTO and CAMBRIDGE, Mass., June 08, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today congratulates Biogen on the recent FDA approval of its monoclonal antibody therapeutic, aducanumab, for the treatment of Alzheimer’s disease (AD).       

After two years of setbacks in the AD field, 2021 has seen significant progress and reason for optimism in the AD community. Biogen’s June 7th FDA approval of aducanumab as well as recent positive clinical trial data from Cassava (simufilam) and Lilly (donanemab) offer further potential positive momentum for AD patients.

“The approval of aducanumab marks the availability of the first disease-modifying therapy for AD, the sixth leading cause of death in the United States,” stated ProMIS Executive Chairman Eugene Williams. “We congratulate Biogen on this important development for AD patients and their caregivers. We now anticipate accelerated interest and support for the development of next generation therapies, such as ProMIS’ PMN310 lead antibody therapeutic for AD. Using our proprietary discovery platform we were able to create an antibody that selectively targets the toxic oligomers of amyloid-beta (A) and avoids undesirable binding to non-toxic forms of amyloid. We believe this high degree of selectivity by PMN310 may offer significant differentiation in terms of efficacy and safety compared to the currently less selective antibody products.”

PMN310, is a humanized monoclonal antibody that binds with high affinity and selectivity to toxic oligomers of A, a recognized root cause of AD. Importantly, PMN310 does not appreciably bind to A plaque or vascular deposits of A thereby reducing the likelihood of brain swelling (edema), a dose-limiting side effect observed with non-selective therapeutic antibodies that interact with A plaque.

About ProMIS Neurosciences, Inc.
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform -ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

For further information about ProMIS Neurosciences, please consult the Company’s website at: www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
nick@alpineequityadv.com
Tel. 617 901-0785

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES15.6.2021 09:30:00 CEST | Press release

Bid date, 2021-06-15Auction date2021-06-15Settlement date2021-06-16Maturity Date2021-06-23Nominal amount484 billion SEKInterest rate, %0.00Bid times09.30-10.00 (CET/CEST) on the Bid dateConfirmation of bids to e-mailrbcert@riksbank.seThe lowest accepted bid volume1 million SEKThe highest accepted bid volume484 billion SEKAllocation Time10.15 (CET/CEST) on the Bid dateProjected minimum liquidity surplus during the term968 billion SEKExpected excess liquidity at full allotment484 billion SEK Stockholm, 2021-06-15

Klövern kommer att sammankalla en extra bolagsstämma enligt begäran från Corem15.6.2021 09:06:03 CEST | Pressemelding

En extra bolagsstämma kommer att hållas i Klövern AB (publ) (”Klövern”) den 9 juli 2021 för val av ny styrelse i enlighet med begäran från Corem. Kallelse utfärdas separat. Corem Property Group AB (publ) (”Corem”) lämnade den 29 mars 2021 ett offentligt uppköpserbjudande till aktieägarna i Klövern. Corem förklarade idag erbjudandet ovillkorat och förlängde acceptfristen till den 23 juni 2021. Corem kontrollerar cirka 89,1 procent av de utestående aktierna och cirka 90,8 procent av rösterna i Klövern. Klövern AB (publ) För ytterligare information, vänligen kontakta: Pia Gideon, styrelseordförande i Klövern Tel: 070-546 71 00 Klövern är ett fastighetsbolag som med närhet och engagemang erbjuder attraktiva lokaler i tillväxtregioner. Klövern är noterat på Nasdaq Stockholm. Ytterligare information finns på www.klovern.se. Klövern AB (publ), Bredgränd 4, 111 30 Stockholm. Tel: 010-482 70 00, Email: info@klovern.se. Detta pressmeddelande har offentliggjorts på svenska och engelska. Vid en ev

Klövern will convene an Extraordinary General Meeting in accordance with a request from Corem15.6.2021 09:06:03 CEST | Press release

An Extraordinary General Meeting will be held in Klövern AB (publ) (”Klövern”) on 9 July 2021 to elect a new Board of Directors in accordance with a request from Corem. A notice will be issued separately. On 29 March 2021, Corem Property Group AB (publ) (”Corem”) announced a public offer to the shareholders of Klövern. Today, Corem declared the offer unconditional and extended the acceptance period to 23 June 2021. Corem controls approximately 89.1 percent of the outstanding shares and approximately 90.8 percent of the votes in Klövern. Klövern AB (publ) For further information, pleasecontact: Pia Gideon, Chairman of the Board of Directors in Klövern Phone: +46 70 546 71 00 Klövern is a real estate company committed to working closely with customers to offer them attractive premises in growth regions. Klövern is listed on Nasdaq Stockholm. For further information, see www.klovern.se. Klövern AB (publ), Bredgränd 4, 111 30 Stockholm. Phone: +46 10 482 70 00. Email: info@klovern.se. This

Ahold Delhaize share buyback update15.6.2021 08:00:00 CEST | Press release

Zaandam, the Netherlands, June 15, 2021 – Ahold Delhaize has repurchased 254,009 of Ahold Delhaize common shares in the period from June 7, 2021 up to and including June 11, 2021. The shares were repurchased at an average price of € 24.58 per share for a total consideration of € 6.2 million. These repurchases were made as part of the €1 billion share buyback program announced on November 4, 2020. The total number of shares repurchased under this program to date is 20,396,452 common shares for a total consideration of € 470.8 million. Download the share buyback transactions excel sheet for detailed individual transaction information from https://www.aholddelhaize.com/en/investors/share-buyback-programs/2021/ This press release is issued in connection with the disclosure and reporting obligation set out in Article 2(2) of the EU Regulation that contains technical standards for buyback programs

Delphix Appoints Proven Industry Leader as Senior Vice President of International Operations15.6.2021 07:00:00 CEST | Press release

Steve Barrett Brings More Than Two Decades of Experience in Enterprise Software, SaaS to Delphix LONDON, June 15, 2021 (GLOBE NEWSWIRE) -- Delphix, the pioneer in programmable data infrastructure, today announced the appointment of Steve Barrett as Senior Vice President of International Operations. Based in the UK, Barrett will be responsible for leading revenue operations for both EMEA and APJ. “Steve’s track record of leading teams to deliver consistent performance and drive customer engagement will be a key advantage for us as we continue to pioneer data automation,” said Steven Chung, President of Worldwide Field Operations at Delphix. “In addition to his domain expertise in DevOps, enterprise apps and data centres, Steve's focus on employee engagement and passion for encouraging diversity, equity and inclusion makes us very excited to welcome him to the Delphix team.” Barrett brings more than 20 years of experience in enterprise software and SaaS companies. He joins Delphix from P

Roche data at EAN 2021 showcase significant impact of therapies across diverse neuroscience portfolio15.6.2021 07:00:00 CEST | Press release

Data for EVRYSDI reinforce safety profile and efficacy in a broad spinal muscular atrophy (SMA) population, following recent EU approvalData for ENSPRYNG in neuromyelitis optica spectrum disorder (NMOSD) build on safety profile and efficacy following recent CHMP opinion, including in adults with concomitant autoimmune diseases (CAIDs) OCREVUS data continue to show consistent benefit on slowing disease progression in relapsing MS (RMS) and primary progressive MS (PPMS)Additional presentations in Alzheimer’s disease (AD), Huntington’s disease (HD) and Parkinson’s disease (PD) continue to contribute to understanding of these complex neurological disorders Basel, 15 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that data across its growing neuroscience portfolio will be presented at the 7th Congress of the European Academy of Neurology (EAN) Annual Meeting being held virtually 19-22 June, 2021. These new and encore data demonstrate Roche’s commitment to advancing the clini